{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:29:40Z","timestamp":1794565780091,"version":"4.9.1"},"reference-count":51,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2010,6,21]],"date-time":"2010-06-21T00:00:00Z","timestamp":1277078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background:\u2002<\/jats:bold> Ocular lesions, the main morbidity of Behcet\u2019s disease (BD), are the most difficult to treat. The aim of this study was to evaluate the efficacy of rituximab.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Inclusion criteria were retinal vasculitis and edema, resistant to cytotoxic drugs. Twenty patients were randomized to a rituximab group (RG) or cytotoxic combination therapy group (CCTG). Rituximab was given in two 1000\u2010mg courses (15\u2010day interval). Subjects received methotrexate (15\u2003mg\/weekly) with prednisolone (0.5\u2003mg\/kg per day). The CCTG received pulse cyclophosphamide (1000\u2003mg\/monthly), azathioprine (2\u20133\u2003mg\/kg per day) and prednisolone (0.5\u2003mg\/kg per day). The primary endpoint was the overall state of patients\u2019 eyes and the Total Adjusted Disease Activity Index (TADAI). Secondary endpoints were: visual acuity (VA), posterior uveitis (PU), and retinal vasculitis (RV). The baseline data were compared at 6\u2003months by paired sample <jats:italic>t<\/jats:italic>\u2010test and analysis of variance.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> TADAI improved significantly in the RG (<jats:italic>t<\/jats:italic>\u2003=\u20033.340, <jats:italic>P\u2003<\/jats:italic>=\u20030.009), but not in the CCTG (<jats:italic>t<\/jats:italic>\u2003=\u20032.241, <jats:italic>P<\/jats:italic>\u2003=\u20030.052). For secondary endpoints (RG\/CCTG), the mean VA improved in two patients versus three (2\/3), remained unchanged in 1\/1, and worsened in 7\/6 patients. The mean PU improved significantly in the RG (<jats:italic>t<\/jats:italic>\u2003=\u20033.943, <jats:italic>P<\/jats:italic>\u2003=\u20030.001), not in the CCTG (<jats:italic>t<\/jats:italic>\u2003=\u20032.371, <jats:italic>P<\/jats:italic>\u2003=\u20030.028). RV improved, but not statistically (<jats:italic>t<\/jats:italic>\u2003=\u20032.027, <jats:italic>P<\/jats:italic>\u2003=\u20030.057 <jats:italic>vs. t<\/jats:italic>\u2003=\u20031.045, <jats:italic>P<\/jats:italic>\u2003=\u20030.31). Edema of retina, disc and macula improved significantly in both, but much better for the RG (<jats:italic>t<\/jats:italic>\u2003=\u20032.781, <jats:italic>P<\/jats:italic>\u2003=\u20030.012 <jats:italic>vs. t<\/jats:italic>\u2003=\u20032.707, <jats:italic>P<\/jats:italic>\u2003=\u20030.014).<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> Rituximab was efficient in severe ocular manifestations of BD, TADAI improved significantly after 6\u2003months with rituximab, but not with CCT.<\/jats:p>","DOI":"10.1111\/j.1756-185x.2010.01546.x","type":"journal-article","created":{"date-parts":[[2010,6,21]],"date-time":"2010-06-21T12:16:05Z","timestamp":1277122565000},"page":"246-252","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":197,"title":["Rituximab in intractable ocular lesions of Behcet\u2019s disease; randomized single\u2010blind control study (pilot study)"],"prefix":"10.1111","volume":"13","author":[{"given":"Fereydoun","family":"DAVATCHI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hormoz","family":"SHAMS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mozhgan","family":"REZAIPOOR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahar","family":"SADEGHI\u2010ABDOLLAHI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"SHAHRAM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdolhadi","family":"NADJI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheyda","family":"CHAMS\u2010DAVATCHI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massoomeh","family":"AKHLAGHI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahereh","family":"FAEZI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasim","family":"NADERI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1756-185X.2010.01462.x"},{"key":"e_1_2_6_3_2","first-page":"298","volume-title":"Textbook of Clinical Rheumatology","author":"Davatchi F","year":"1998"},{"key":"e_1_2_6_4_2","first-page":"314","article-title":"Beh\u00e7et\u2019s disease and immunosuppressive treatment. Our personal experience","volume":"16","author":"Bietti GB","year":"1976","journal-title":"Mod Probl Ophthalmol"},{"key":"e_1_2_6_5_2","first-page":"1421","article-title":"Results of immunosuppressive treatment in Bech\u00e7et\u2019s disease: report of 55 cases","volume":"10","author":"Firat T","year":"1978","journal-title":"Ann Ophthalmol"},{"key":"e_1_2_6_6_2","first-page":"455","article-title":"Immunosuppressive therapy of Behcet\u2019s syndrome. Long term follow\u2010up evaluation (author\u2019s transl)","volume":"4","author":"Bonnet M","year":"1981","journal-title":"J Fr Ophtalmol"},{"key":"e_1_2_6_7_2","first-page":"404","article-title":"Cyclophosphamide in the treatment of the ocular manifestations of Behcet\u2019s disease","volume":"11","author":"Davatchi F","year":"1984","journal-title":"J Rheumatol"},{"key":"e_1_2_6_8_2","first-page":"387","volume-title":"Ophthalmology Today","author":"Davatchi F","year":"1988"},{"key":"e_1_2_6_9_2","first-page":"1355","article-title":"Value of \u201cbolus\u201d cyclophosphamide injections in Beh\u00e7et\u2019s disease. Experience of 17 cases","volume":"19","author":"Du LT","year":"1990","journal-title":"Presse Med"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.74.6.353"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1046132"},{"key":"e_1_2_6_12_2","first-page":"555","volume-title":"Behcet\u2019s Disease Basic and Clinical Aspects","author":"Davatchi F","year":"1991"},{"key":"e_1_2_6_13_2","first-page":"569","volume-title":"Behcet\u2019s Disease, Basic and Clinical Aspects","author":"Le Thi Huong D","year":"1991"},{"key":"e_1_2_6_14_2","first-page":"438","article-title":"Bolus of cyclophosphamide and methylprednisolone in uveitis in Behcet\u2019s disease. Preliminary results with the use of new criteria of evaluation","volume":"143","author":"Hamza M","year":"1992","journal-title":"Ann Med Interne"},{"key":"e_1_2_6_15_2","first-page":"683","volume-title":"Behcet\u2019s Disease","author":"Shahram F","year":"1993"},{"key":"e_1_2_6_16_2","first-page":"635","volume-title":"Behcet\u2019s Disease","author":"Shahram F","year":"1993"},{"key":"e_1_2_6_17_2","first-page":"S217","article-title":"Outcome analysis of ocular lesions in Behcet\u2019s Disease with 6 different therapeutic methods","volume":"39","author":"Davatchi F","year":"1996","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.3109\/08830189709116844"},{"key":"e_1_2_6_19_2","first-page":"421","volume-title":"Behcet\u2019s Disease","author":"Shahram F","year":"1997"},{"key":"e_1_2_6_20_2","first-page":"524","article-title":"Value of the cyclophosphamide bolus in severe systemic diseases. Preliminary results","volume":"17","author":"Le Thi Huong D","year":"1998","journal-title":"Presse Med"},{"key":"e_1_2_6_21_2","first-page":"S356","article-title":"Methotrexate for ocular lesions of Behcet\u2019s Disease. Cohort study on 262 patients","volume":"41","author":"Davatchi F","year":"1998","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-5155(99)00029-5"},{"key":"e_1_2_6_23_2","first-page":"1999","article-title":"Eye and Behcet\u2019s Disease","volume":"49","author":"Binisti P","year":"1999","journal-title":"Rev Prat"},{"key":"e_1_2_6_24_2","first-page":"898","volume-title":"Behcet\u2019s Disease","author":"Davatchi F","year":"2000"},{"key":"e_1_2_6_25_2","first-page":"7","article-title":"Ocular Behcet\u2019s disease: procedural aspects","volume":"280","author":"Postelmans L","year":"2001","journal-title":"Bull Soc Belge Ophtalmol"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/0-306-48382-3_118"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/0-306-48382-3_116"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/0-306-48382-3_99"},{"key":"e_1_2_6_29_2","first-page":"3","article-title":"Longitudinal study of chlorambucil in ocular manifestations of Behcet\u2019s Disease","volume":"21","author":"Davatchi F","year":"2009","journal-title":"Iranian J Ophthalmol"},{"key":"e_1_2_6_30_2","first-page":"201","article-title":"Pulse cyclophosphamide in ocular manifestations of Behcet\u2019s Disease. A double blind crossover study","volume":"7","author":"Davatchi F","year":"2004","journal-title":"Arch Iranian Med"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/0-306-48382-3_100"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1479-8077.2005.00139.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2003.09.005"},{"key":"e_1_2_6_34_2","first-page":"1241","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet\u2019s Disease with refractory uveroretinitis","volume":"31","author":"Ohno S","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21231"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206939"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1078\/0171-2985-00200"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032534"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20430"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2005.075689"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.047308"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-008-0057-9"},{"issue":"42","key":"e_1_2_6_43_2","first-page":"S14","article-title":"Revision of the International Criteria for Behcet\u2019s Disease (ICBD)","volume":"24","author":"International Team for the Revision of the International Criteria for Behcet\u2019s Disease (ITR\u2010ICBD)","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_44_2","volume-title":"Uveitis Scoring System","author":"Ben Ezra D"},{"key":"e_1_2_6_45_2","first-page":"128","article-title":"Systemic levels of the T cell regulatory cytokines IL\u201010 and IL\u201012 in Behcet\u2019s disease; soluble TNFR\u201075 as a biological marker of disease activity","volume":"24","author":"Turan B","year":"1997","journal-title":"J Rheumatol"},{"issue":"5","key":"e_1_2_6_46_2","first-page":"S6","article-title":"Behcet\u2019s disease: an update on the pathogenesis","volume":"19","author":"Gul A","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1159\/000055677"},{"key":"e_1_2_6_48_2","first-page":"115","volume-title":"Rheumatology APLAR 1992","author":"Massoud A","year":"1992"},{"key":"e_1_2_6_49_2","first-page":"826","article-title":"Phenotypic characteristics of B cells in Beh\u00e7et\u2019s disease: increased activity in B cell subsets","volume":"26","author":"Ek\u015fioglu\u2010Demiralp E","year":"1999","journal-title":"J Rheumatol"},{"key":"e_1_2_6_50_2","first-page":"487","volume-title":"Behcet\u2019s Disease Basic and Clinical Aspects","author":"Celenligil H","year":"1991"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.3109\/08916939209148460"},{"key":"e_1_2_6_52_2","first-page":"345","article-title":"Aqueous humor and serum interleukin\u20106 in patients with uveitis","volume":"76","author":"Santos Lacomba M","year":"2001","journal-title":"Arch Soc Esp Oftalmol"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1756-185X.2010.01546.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1756-185X.2010.01546.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T11:01:43Z","timestamp":1698750103000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1756-185X.2010.01546.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1111\/j.1756-185X.2010.01546.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1756-185x.2010.01546.x","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8]]},"assertion":[{"value":"2010-08-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}